Immunobiology of Human Cytomegalovirus: from Bench to Bedside

SUMMARY Following primary infection, human cytomegalovirus (HCMV) establishes lifelong latency and periodically reactivates without causing symptoms in healthy individuals. In the absence of an adequate host-derived immune response, this fine balance of permitting viral reactivation without causing pathogenesis is disrupted, and HCMV can subsequently cause invasive disease and an array of damaging indirect immunological effects. Over the last decade, our knowledge of the immune response to HCMV infection in healthy virus carriers and diseased individuals has allowed us to translate these findings to develop better diagnostic tools and therapeutic strategies. The application of these emerging technologies in the clinical setting is likely to provide opportunities for better management of patients with HCMV-associated diseases.

[1]  A. Zimmermann,et al.  Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. , 2008, The Journal of general virology.

[2]  L. Cooper,et al.  Induction of Pluripotent Protective Immunity Following Immunisation with a Chimeric Vaccine against Human Cytomegalovirus , 2008, PloS one.

[3]  D. Lilleri,et al.  Human cytomegalovirus-specific memory CD8+ and CD4+ T cell differentiation after primary infection. , 2008, The Journal of infectious diseases.

[4]  T. Kotsimbos,et al.  Linking CMV Serostatus to Episodes of CMV Reactivation Following Lung Transplantation by Measuring CMV‐Specific CD8+ T‐Cell Immunity , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  P. Klenerman,et al.  Functional Impairment of Cytomegalovirus Specific CD8 T Cells Predicts High‐Level Replication After Renal Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  J. McCluskey,et al.  Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection. , 2008, Blood.

[7]  T. Compton,et al.  Differential Initiation of Innate Immune Responses Induced by Human Cytomegalovirus Entry into Fibroblast Cells1 , 2008, The Journal of Immunology.

[8]  T. Lazzarotto,et al.  New advances in the diagnosis of congenital cytomegalovirus infection. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  P. Moss,et al.  CD4+ T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. , 2008, Blood.

[10]  P. Bjorkman,et al.  The Human Cytomegalovirus Fc Receptor gp68 Binds the Fc CH2-CH3 Interface of Immunoglobulin G , 2008, Journal of Virology.

[11]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[12]  L. Picker,et al.  Induction and Evolution of Cytomegalovirus-Specific CD4+ T Cell Clonotypes in Rhesus Macaques1 , 2008, The Journal of Immunology.

[13]  H. Ljunggren,et al.  Human cytomegalovirus‐derived protein UL18 alters the phenotype and function of monocyte‐derived dendritic cells , 2008, Journal of leukocyte biology.

[14]  W. Chu,et al.  IFN-αβ-Mediated Inflammatory Responses and Antiviral Defense in Liver Is TLR9-Independent but MyD88-Dependent during Murine Cytomegalovirus Infection1 , 2007, The Journal of Immunology.

[15]  I. T. Ten Berge,et al.  Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus1 , 2007, The Journal of Immunology.

[16]  A. Swerdlow,et al.  Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. , 2007, Blood.

[17]  M. Davenport,et al.  Symptomatic and Asymptomatic Viral Recrudescence in Solid-Organ Transplant Recipients and Its Relationship with the Antigen-Specific CD8+ T-Cell Response , 2007, Journal of Virology.

[18]  M. Reeves,et al.  Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. , 2007, Blood.

[19]  D. Lilleri,et al.  Inconsistent Responses of Cytomegalovirus‐Specific T Cells to pp65 and IE‐1 versus Infected Dendritic Cells in Organ Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  K. P. Singh,et al.  Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery. , 2007, Clinical immunology.

[21]  W. Drew,et al.  Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients , 2007, Current opinion in infectious diseases.

[22]  R. Rubin The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the ‘silo hypothesis’ , 2007, Current opinion in infectious diseases.

[23]  Drew Wl Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. , 2007 .

[24]  Hanah Margalit,et al.  Host Immune System Gene Targeting by a Viral miRNA , 2007, Science.

[25]  M. Cannon,et al.  Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection , 2007, Reviews in medical virology.

[26]  J. Safrit,et al.  Depletion of CD8+ Cells in Sooty Mangabey Monkeys Naturally Infected with Simian Immunodeficiency Virus Reveals Limited Role for Immune Control of Virus Replication in a Natural Host Species1 , 2007, The Journal of Immunology.

[27]  G. Malm,et al.  Congenital cytomegalovirus infections. , 2007, Seminars in fetal & neonatal medicine.

[28]  R. Khanna,et al.  Ex vivo monitoring of human cytomegalovirus‐specific CD8+ T‐cell responses using QuantiFERON®‐CMV , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[29]  Peter Shaw,et al.  Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  P. Ljungman Risk assessment in haematopoietic stem cell transplantation: viral status. , 2007, Best practice & research. Clinical haematology.

[31]  Marcos González,et al.  Monoclonal TCR-Vbeta13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. , 2007, Blood.

[32]  R. Khanna,et al.  Vaccine strategies against human cytomegalovirus infection , 2007, Expert review of anti-infective therapy.

[33]  P. Moss,et al.  The Cytomegalovirus-Specific CD4+ T-Cell Response Expands with Age and Markedly Alters the CD4+ T-Cell Repertoire , 2007, Journal of Virology.

[34]  P. Moss,et al.  T Cell Recognition Patterns of Immunodominant Cytomegalovirus Antigens in Primary and Persistent Infection , 2007, The Journal of Immunology.

[35]  Y. Belkaid,et al.  Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. , 2007, The Journal of infectious diseases.

[36]  L. Pereira,et al.  Recent advances in the prevention and treatment of congenital cytomegalovirus infections. , 2007, Seminars in perinatology.

[37]  J. Fritz,et al.  Vanishing bile duct syndrome in a patient with advanced AIDS , 2007, HIV medicine.

[38]  R. Koup,et al.  Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation , 2006, The Journal of experimental medicine.

[39]  A. Cunningham,et al.  Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. , 2006, Blood.

[40]  A. Limaye,et al.  Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. , 2006, The Journal of infectious diseases.

[41]  T. Compton,et al.  Human Cytomegalovirus Envelope Glycoproteins B and H Are Necessary for TLR2 Activation in Permissive Cells1 , 2006, The Journal of Immunology.

[42]  W. Flanders,et al.  Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  D. Lilleri,et al.  Monitoring of Human Cytomegalovirus‐Specific CD4+ and CD8+ T‐Cell Immunity in Patients Receiving Solid Organ Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  Chung-Che Chang,et al.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals , 2006, Nature Medicine.

[45]  A. McGregor,et al.  Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine. , 2006, Vaccine.

[46]  E. Puchhammer-Stöckl,et al.  Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[47]  J. Sinclair,et al.  Latency and reactivation of human cytomegalovirus. , 2006, The Journal of general virology.

[48]  Lihan K. Yan,et al.  A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. , 2006, The Journal of infectious diseases.

[49]  P. Griffiths CMV as a cofactor enhancing progression of AIDS. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[50]  T. Kotsimbos,et al.  CMV‐Specific CD8+ T‐Cell Dynamics in the Blood and the Lung Allograft Reflect Viral Reactivation Following Lung Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[51]  J. Orens,et al.  Persistent Cytomegalovirus-Specific Memory Responses in the Lung Allograft and Blood following Primary Infection in Lung Transplant Recipients1 , 2006, The Journal of Immunology.

[52]  A. Humar,et al.  American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[53]  W. Britt,et al.  Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[54]  S. Boppana,et al.  Congenital cytomegalovirus (CMV) infection and hearing deficit. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[55]  H. Doerr,et al.  Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[56]  P. Desgranges,et al.  Risk Factors and Long‐Term Outcome of Transplant Renal Artery Stenosis in Adult Recipients After Treatment by Percutaneous Transluminal Angioplasty , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[57]  J. Trowsdale,et al.  Human Cytomegalovirus Encodes an MHC Class I-Like Molecule (UL142) That Functions to Inhibit NK Cell Lysis1 , 2005, The Journal of Immunology.

[58]  M. Schleiss Progress in cytomegalovirus vaccine development. , 2005, Herpes : the journal of the IHMF.

[59]  S. Migueles,et al.  Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses , 2005, The Journal of experimental medicine.

[60]  S. Akira,et al.  MyD88-Dependent and -Independent Murine Cytomegalovirus Sensing for IFN-α Release and Initiation of Immune Responses In Vivo1 , 2005, The Journal of Immunology.

[61]  P. Lehner,et al.  An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. , 2005, The Journal of general virology.

[62]  L. Folgueira,et al.  Comparison of cytomegalovirus viral load measure by real-time PCR with pp65 antigenemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients. , 2005, Transplantation proceedings.

[63]  M. Jarvis,et al.  Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL , 2005, Journal of Experimental Medicine.

[64]  J. Neefjes,et al.  MHC class I alleles and their exploration of the antigen‐processing machinery , 2005, Immunological reviews.

[65]  Peter Cresswell,et al.  Mechanisms of MHC class I‐restricted antigen processing and cross‐presentation , 2005, Immunological reviews.

[66]  A. Best,et al.  Passive immunization during pregnancy for congenital cytomegalovirus infection. , 2005, The New England journal of medicine.

[67]  Louis J. Picker,et al.  Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects , 2005, The Journal of experimental medicine.

[68]  J. Maciejewski,et al.  Characterization of an Antisense Transcript Spanning the UL81-82 Locus of Human Cytomegalovirus , 2005, Journal of Virology.

[69]  C. Craddock,et al.  Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers , 2005, The Journal of experimental medicine.

[70]  W. Bresnahan,et al.  Interaction between the Human Cytomegalovirus UL82 Gene Product (pp71) and hDaxx Regulates Immediate-Early Gene Expression and Viral Replication , 2005, Journal of Virology.

[71]  H. Schäfers,et al.  Differences in CMV‐Specific T‐Cell Levels and Long‐Term Susceptibility to CMV Infection after Kidney, Heart and Lung Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[72]  D. Lilleri,et al.  Simultaneous quantification of human cytomegalovirus (HCMV)‐specific CD4+ and CD8+ T cells by a novel method using monocyte‐derived HCMV‐infected immature dendritic cells , 2005, European journal of immunology.

[73]  G. Pawelec,et al.  Human immunosenescence: is it infectious? , 2005, Immunological reviews.

[74]  H. de la Salle,et al.  Shared reactivity of Vδ2neg γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells , 2005, The Journal of experimental medicine.

[75]  Ofer Levi,et al.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus , 2005, Nature Immunology.

[76]  R. Hetzer,et al.  Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells , 2005, The Journal of experimental medicine.

[77]  L. Cooper,et al.  Ex vivo expansion of human cytomegalovirus‐specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy , 2005, European journal of immunology.

[78]  P. Moss,et al.  Identification of Cytomegalovirus-Specific Cytotoxic T Lymphocytes In Vitro Is Greatly Enhanced by the Use of Recombinant Virus Lacking the US2 to US11 Region or Modified Vaccinia Virus Ankara Expressing Individual Viral Genes , 2005, Journal of Virology.

[79]  I. T. Ten Berge,et al.  Clinical and Immunologic Aspects of Cytomegalovirus Infection in Solid Organ Transplant Recipients , 2005, Transplantation.

[80]  P. Tomasec,et al.  Downregulation of natural killer cell–activating ligand CD155 by human cytomegalovirus UL141 , 2005, Nature Immunology.

[81]  M. Davenport,et al.  Contemporaneous fluctuations in T cell responses to persistent herpes virus infections , 2005, European journal of immunology.

[82]  S. Jordan,et al.  Cellular Immune Responses to Cytomegalovirus in Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[83]  P. Moss,et al.  Herpesvirus-Specific CD8 T Cell Immunity in Old Age: Cytomegalovirus Impairs the Response to a Coresident EBV Infection1 , 2004, The Journal of Immunology.

[84]  R. Khanna,et al.  Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. , 2004, The Lancet. Infectious diseases.

[85]  R. Khanna,et al.  Cross‐reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H , 2004, European journal of immunology.

[86]  Richard D. Smith,et al.  Identification of Proteins in Human Cytomegalovirus (HCMV) Particles: the HCMV Proteome , 2004, Journal of Virology.

[87]  S. Riddell,et al.  Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. , 2004, Blood.

[88]  T. Compton,et al.  Innate Sensing of Viruses by Toll-Like Receptors , 2004, Journal of Virology.

[89]  EuroSIDA,et al.  Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994–2001 , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[90]  James W. Young,et al.  Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. , 2004, Blood.

[91]  K. Lucas,et al.  Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes for recurrent, EBV‐positive Hodgkin disease , 2004, Cancer.

[92]  H. Einsele,et al.  Clinical aspects of CMV infection after stem cell transplantation. , 2004, Human immunology.

[93]  M. V. Van Natta,et al.  Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. , 2004, The Journal of infectious diseases.

[94]  D. Bernstein,et al.  Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. , 2004, The Journal of infectious diseases.

[95]  B. Alexander,et al.  Clinical Utility of Cytomegalovirus Viral Load Testing for Predicting CMV Disease in D+/R‐ Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[96]  Yuping Deng,et al.  Age-Related Impaired Type 1 T Cell Responses to Influenza: Reduced Activation Ex Vivo, Decreased Expansion in CTL Culture In Vitro, and Blunted Response to Influenza Vaccination In Vivo in the Elderly1 , 2004, The Journal of Immunology.

[97]  Michael Boeckh,et al.  The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. , 2004, Blood.

[98]  R. Flavell,et al.  Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[99]  H. Maecker,et al.  Persistent and Selective Deficiency of CD4+ T Cell Immunity to Cytomegalovirus in Immunocompetent Young Children1 , 2004, The Journal of Immunology.

[100]  S. Perez,et al.  Natural killer lymphocytes: biology, development, and function , 2004, Cancer Immunology, Immunotherapy.

[101]  B. Slobedman,et al.  A Novel Viral Transcript with Homology to Human Interleukin-10 Is Expressed during Latent Human Cytomegalovirus Infection , 2004, Journal of Virology.

[102]  M. Tanimoto,et al.  Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. , 2004, Blood.

[103]  H. Einsele,et al.  Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. , 2003, Blood.

[104]  P. Casarosa,et al.  Human Cytomegalovirus Chemokine Receptor US28-induced Smooth Muscle Cell Migration Is Mediated by Focal Adhesion Kinase and Src* , 2003, Journal of Biological Chemistry.

[105]  P. Moss,et al.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines , 2003, The Lancet.

[106]  P. Klenerman,et al.  Memory Inflation: Continous Accumulation of Antiviral CD8+ T Cells Over Time , 2003, The Journal of Immunology.

[107]  J. Myśliwska,et al.  Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination--an impact of immunosenescence. , 2003, Vaccine.

[108]  G. Papanicolaou,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[109]  G. Pawelec,et al.  Large Numbers of Dysfunctional CD8+ T Lymphocytes Bearing Receptors for a Single Dominant CMV Epitope in the Very Old , 2003, Journal of Clinical Immunology.

[110]  S. Rowland-Jones,et al.  Mature CD8(+) T lymphocyte response to viral infection during fetal life. , 2003, The Journal of clinical investigation.

[111]  M. Menzies,et al.  Ex Vivo Profiling of CD8+-T-Cell Responses to Human Cytomegalovirus Reveals Broad and Multispecific Reactivities in Healthy Virus Carriers , 2003, Journal of Virology.

[112]  D. Golenbock,et al.  Human Cytomegalovirus Activates Inflammatory Cytokine Responses via CD14 and Toll-Like Receptor 2 , 2003, Journal of Virology.

[113]  K. Wong,et al.  Cytomegalovirus infection associated with clonal proliferation of T-cell large granular lymphocytes: causal or casual? , 2003, Cancer genetics and cytogenetics.

[114]  E. Remmerswaal,et al.  Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. , 2003, Blood.

[115]  P. Klenerman,et al.  Regulation of the Class II MHC Pathway in Primary Human Monocytes by Granulocyte-Macrophage Colony-Stimulating Factor 1 , 2003, The Journal of Immunology.

[116]  Yuping Deng,et al.  Vigorous Innate and Virus-Specific Cytotoxic T-Lymphocyte Responses to Murine Cytomegalovirus in the Submaxillary Salivary Gland , 2003, Journal of Virology.

[117]  F. Goodrum,et al.  Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: A model for latency , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[118]  H. Ploegh,et al.  The Human Cytomegalovirus US10 Gene Product Delays Trafficking of Major Histocompatibility Complex Class I Molecules , 2002, Journal of Virology.

[119]  H. Rollag,et al.  The Impact of Cytomegalovirus Infection and Disease on Rejection Episodes in Renal Allograft Recipients , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[120]  B. Gärtner,et al.  Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. , 2002, Journal of the American Society of Nephrology : JASN.

[121]  W. Leisenring,et al.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. , 2002, Blood.

[122]  M. Messerle,et al.  Identification and Expression of Human Cytomegalovirus Transcription Units Coding for Two Distinct Fcγ Receptor Homologs , 2002, Journal of Virology.

[123]  P. Moss,et al.  Cytomegalovirus Seropositivity Drives the CD8 T Cell Repertoire Toward Greater Clonality in Healthy Elderly Individuals1 , 2002, The Journal of Immunology.

[124]  S. Plotkin Is there a formula for an effective CMV vaccine? , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[125]  E. Mocarski Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. , 2002, Trends in microbiology.

[126]  Holden T Maecker,et al.  Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. , 2002, The Journal of infectious diseases.

[127]  L. Picker,et al.  Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. , 2002, The Journal of infectious diseases.

[128]  Hans-Georg Rammensee,et al.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. , 2002, Blood.

[129]  H. Rammensee,et al.  Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. , 2002, Blood.

[130]  P. Moss,et al.  Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. , 2002, The Journal of infectious diseases.

[131]  B. Gärtner,et al.  Sustained High Frequencies of Specific CD4 T Cells Restricted to a Single Persistent Virus , 2002, Journal of Virology.

[132]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[133]  H. Deeg,et al.  Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. , 2002, Blood.

[134]  J. Sissons,et al.  Clinical aspects and management of cytomegalovirus infection. , 2002, The Journal of infection.

[135]  M. Wills,et al.  Latency and reactivation of human cytomegalovirus. , 2002, The Journal of infection.

[136]  R. Burke,et al.  Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. , 2002, The Pediatric infectious disease journal.

[137]  M. Boeckh,et al.  High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. , 2002, The Journal of infectious diseases.

[138]  H. Ploegh,et al.  Human Cytomegalovirus Open Reading Frame TRL11/IRL11 Encodes an Immunoglobulin G Fc-Binding Protein , 2001, Journal of Virology.

[139]  C Anasetti,et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.

[140]  C. Tournay,et al.  Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. , 2001, Blood.

[141]  J. Garcia-conde,et al.  Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)‐specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant , 2001, Journal of medical virology.

[142]  J. Moreau,et al.  Cytomegalovirus Infection in Transplant Recipients Resolves When Circulating γδ T Lymphocytes Expand, Suggesting a Protective Antiviral Role , 2001 .

[143]  C. Pitcher,et al.  Clonotypic Structure of the Human CD4+ Memory T Cell Response to Cytomegalovirus1 , 2001, The Journal of Immunology.

[144]  J. Sprent,et al.  T Cell Death and Memory , 2001, Science.

[145]  C. Sutherland,et al.  The UL16‐binding proteins, a novel family of MHC class I‐related ligands for NKG2D, activate natural killer cell functions , 2001, Immunological reviews.

[146]  T. Chittenden,et al.  A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[147]  W. Britt,et al.  Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. , 2001, The Journal of infectious diseases.

[148]  A. Meyerhans,et al.  LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1 , 2001, Transplantation.

[149]  Jonathan W. Heusel,et al.  Vital Involvement of a Natural Killer Cell Activation Receptor in Resistance to Viral Infection , 2001, Science.

[150]  W. Cox,et al.  A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. , 2001, The Journal of infectious diseases.

[151]  R. Armitage,et al.  ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. , 2001, Immunity.

[152]  P. Mathew,et al.  T‐gamma gene rearrangement and CMV mononucleosis , 2001, American journal of hematology.

[153]  E. Mocarski,et al.  Human Cytomegalovirus Latency-Associated Protein pORF94 Is Dispensable for Productive and Latent Infection , 2000, Journal of Virology.

[154]  J. Bell,et al.  Functional Heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8+ T Lymphocytes in Healthy Seropositive Donors , 2000, Journal of Virology.

[155]  H. Volk,et al.  A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. , 2000, Virology.

[156]  C. Katlama,et al.  Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy , 2000, AIDS.

[157]  C. Sabin,et al.  Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. , 2000, The Journal of infectious diseases.

[158]  V. Kuenen-Boumeester,et al.  Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. , 2000, Blood.

[159]  H. Einsele,et al.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection , 2000, Bone Marrow Transplantation.

[160]  T. Lazzarotto,et al.  Humoral immune response to proteins of human cytomegalovirus latency-associated transcripts. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[161]  V. Maino,et al.  Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. , 2000, The Journal of infectious diseases.

[162]  S. Pestka,et al.  Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[163]  A. McMichael,et al.  Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. , 2000, Science.

[164]  H. Yoshida,et al.  Vγ1+γδ T cells play protective roles at an early phase of murine cytomegalovirus infection through production of interferon‐γ , 2000 .

[165]  G. Alexander,et al.  An association between cytomegalovirus infection and chronic rejection after liver transplantation. , 2000, Transplantation.

[166]  R. Sekulovich,et al.  Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. , 1999, The Journal of infectious diseases.

[167]  P. Bjorkman,et al.  The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. , 1999, Immunity.

[168]  E. Kieff,et al.  A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[169]  W. Britt,et al.  A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. , 1999, The Journal of infectious diseases.

[170]  J. Schneider-Mergener,et al.  Target Structures of the CD8+-T-Cell Response to Human Cytomegalovirus: the 72-Kilodalton Major Immediate-Early Protein Revisited , 1999, Journal of Virology.

[171]  P. Cresswell,et al.  Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells , 1999, Nature Medicine.

[172]  T. Schall,et al.  Cytomegalovirus encodes a potent alpha chemokine. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[173]  G. Cathomas,et al.  Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. , 1999, The Journal of infectious diseases.

[174]  Z. Zhou,et al.  Three-dimensional visualization of tegument/capsid interactions in the intact human cytomegalovirus. , 1999, Virology.

[175]  J. Corbeil,et al.  Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. , 1999, Journal of immunology.

[176]  E. Mocarski,et al.  Quantitative Analysis of Latent Human Cytomegalovirus , 1999, Journal of Virology.

[177]  M. Bonneville,et al.  Implication of γδ T cells in the human immune response to cytomegalovirus , 1999 .

[178]  D. Sedmak,et al.  Human Cytomegalovirus Inhibits IFN-α-Stimulated Antiviral and Immunoregulatory Responses by Blocking Multiple Levels of IFN-α Signal Transduction , 1999, The Journal of Immunology.

[179]  W. Cox,et al.  A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). , 1999, The Journal of infectious diseases.

[180]  M. Bonneville,et al.  Implication of gammadelta T cells in the human immune response to cytomegalovirus. , 1999, The Journal of clinical investigation.

[181]  S. Plotkin Vaccination against cytomegalovirus, the changeling demon. , 1999, The Pediatric infectious disease journal.

[182]  D. Cosman,et al.  Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers , 1999, Immunological reviews.

[183]  W. Freeman,et al.  Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. , 1999, The Journal of infectious diseases.

[184]  T. Schwartz,et al.  Selective recognition of the membrane‐bound CX3C chemokine, fractalkine, by the human cytomegalovirus‐encoded broad‐spectrum receptor US28 , 1998, FEBS letters.

[185]  H. Einsele,et al.  Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. , 1998, The Journal of infectious diseases.

[186]  S. Jonjić,et al.  Hierarchical and Redundant Lymphocyte Subset Control Precludes Cytomegalovirus Replication during Latent Infection , 1998, The Journal of experimental medicine.

[187]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[188]  P. Bjorkman,et al.  Modulation of Natural Killer Cell Cytotoxicity in Human Cytomegalovirus Infection: The Role of Endogenous Class I Major Histocompatibility Complex and a Viral Class I Homolog , 1998, The Journal of experimental medicine.

[189]  H. Hackstein,et al.  High incidence of active cytomegalovirus infection among septic patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[190]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[191]  D. Sedmak,et al.  Human Cytomegalovirus Inhibits Major Histocompatibility Complex Class II Expression By Disruption of the Jak/Stat Pathway , 1998, The Journal of experimental medicine.

[192]  B. Hendry,et al.  CMV infection is associated with transplant renal artery stenosis. , 1998, QJM : monthly journal of the Association of Physicians.

[193]  S. Riddell,et al.  Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. , 1998, The Pediatric infectious disease journal.

[194]  R. Wiesner,et al.  Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. , 1997, The Journal of infectious diseases.

[195]  J. Griffith,et al.  Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. , 1997, Clinical transplantation.

[196]  E. Elias,et al.  Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[197]  D. Snydman,et al.  The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. , 1997, The American journal of medicine.

[198]  R. Bolman,et al.  Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. , 1997, The Journal of thoracic and cardiovascular surgery.

[199]  J. Bluestone,et al.  T Cell Receptor–γ/δ Cells Protect Mice from Herpes Simplex Virus Type 1–induced Lethal Encephalitis , 1997, The Journal of experimental medicine.

[200]  H. Einsele,et al.  Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease , 1997, Bone Marrow Transplantation.

[201]  P. A. Peterson,et al.  The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. , 1997, Immunity.

[202]  O. Mandelboim,et al.  The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells , 1997, Nature.

[203]  L. Sun,et al.  Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains , 1997, Journal of virology.

[204]  K. Salmela,et al.  Persistent cytomegalovirus in liver allografts with chronic rejection , 1997 .

[205]  J. Sinclair,et al.  Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. , 1996, The Journal of general virology.

[206]  W. Gibson,et al.  Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. , 1996, Virology.

[207]  S. Riddell,et al.  Cytomegalovirus selectively blocks antigen processing and presentation of its immediate–early gene product , 1996, Nature.

[208]  H. Ploegh,et al.  Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[209]  J. Xu,et al.  Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[210]  A. Fiander,et al.  Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B , 1996, Journal of medical virology.

[211]  J. Davignon,et al.  Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro , 1996, Journal of virology.

[212]  M. Bogyo,et al.  The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class I Heavy Chains from the Endoplasmic Reticulum to the Cytosol , 1996, Cell.

[213]  R. Spaete,et al.  Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids , 1996, Journal of virology.

[214]  W. Britt,et al.  Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. , 1995, The Journal of infectious diseases.

[215]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[216]  N. G. Best,et al.  Blood cyclosporine concentrations and cytomegalovirus infection following heart transplantation. , 1995, Transplantation.

[217]  D. Bernstein,et al.  Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. , 1995, The Journal of infectious diseases.

[218]  B. Griffith,et al.  Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. , 1995, The Journal of thoracic and cardiovascular surgery.

[219]  W. Britt,et al.  Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. , 1995, The Journal of infectious diseases.

[220]  A. Gouw,et al.  Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. , 1995, The Journal of general virology.

[221]  R. Wiesner,et al.  OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. , 1995, The Journal of infectious diseases.

[222]  H. Volk,et al.  Stimulation of the Human Cytomegalovirus IE Enhancer/Promoter in HL-60 Cells by TNFα Is Mediated via Induction of NF-κB , 1995 .

[223]  D. Snydman,et al.  Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates , 1995, The Pediatric infectious disease journal.

[224]  E. Mocarski,et al.  Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[225]  S. Spector,et al.  MULTICENTER TRIAL OF TOWNE STRAIN ATTENUATED VIRUS VACCINE IN SERONEGATIVE RENAL TRANSPLANT RECIPIENTS , 1994, Transplantation.

[226]  P. Murphy,et al.  Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. , 1994, The Journal of biological chemistry.

[227]  F. Emmrich,et al.  CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS THE ROLE OF TUMOR NECROSIS FACTOR , 1994, Transplantation.

[228]  S. Jonjić,et al.  Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus , 1994, The Journal of experimental medicine.

[229]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.

[230]  A. Messori,et al.  Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. , 1994, Bone marrow transplantation.

[231]  M. van der Giessen,et al.  Natural killer cell responses in renal transplant patients with cytomegalovirus infection , 1994, Journal of medical virology.

[232]  H. Volk,et al.  Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. , 1993, The Journal of general virology.

[233]  M. Nieminen,et al.  Cytomegalovirus infection accelerates cardiac allograft vasculopathy: correlation between angiographic and endomyocardial biopsy findings in heart transplant patients , 1993, Transplant international : official journal of the European Society for Organ Transplantation.

[234]  M. Messerle,et al.  Lungs are a major organ site of cytomegalovirus latency and recurrence , 1993, Journal of virology.

[235]  S. Riddell,et al.  Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus , 1993, Journal of virology.

[236]  S. Larsson,et al.  Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection , 1993, Journal of virology.

[237]  T. Schall,et al.  Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor , 1993, Cell.

[238]  M. van der Giessen,et al.  Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. , 1993, The Journal of infectious diseases.

[239]  R. Chaisson,et al.  Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. , 1992, The Journal of infectious diseases.

[240]  B. Portmann,et al.  Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome , 1992, Hepatology.

[241]  R. Burton,et al.  The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. , 1992, Journal of immunology.

[242]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[243]  W. Britt,et al.  The outcome of congenital cytomegalovirus infection in relation to maternal antibody status , 1992, The New England journal of medicine.

[244]  G. Rabalais,et al.  Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. , 1992, The Journal of infectious diseases.

[245]  J. Meyers,et al.  Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. , 1991, The New England journal of medicine.

[246]  T. Merigan,et al.  Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. , 1991, The Journal of infectious diseases.

[247]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[248]  J. Sissons,et al.  Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. , 1991, The Journal of general virology.

[249]  J. Niland,et al.  A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants , 1991 .

[250]  H. Friedman,et al.  Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. , 1991, Annals of internal medicine.

[251]  S. Jonjić,et al.  Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes , 1990, Journal of virology.

[252]  A. Scalzo,et al.  Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen , 1990, The Journal of experimental medicine.

[253]  B. Barrell,et al.  Human cytomegalovirus encodes three G protein-coupled receptor homologues , 1990, Nature.

[254]  W. Ho,et al.  Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. , 1990, Vaccine.

[255]  W. Britt,et al.  Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response , 1990, Journal of virology.

[256]  T. Rector,et al.  Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. , 1989, The American journal of cardiology.

[257]  P. Griffiths,et al.  CYTOMEGALOVIRUS INFECTION AND PROGRESSION TOWARDS AIDS IN HAEMOPHILIACS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION , 1989, The Lancet.

[258]  J L Sullivan,et al.  Severe herpesvirus infections in an adolescent without natural killer cells. , 1989, The New England journal of medicine.

[259]  V. Starnes,et al.  Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. , 1989, JAMA.

[260]  B. Portmann,et al.  CYTOMEGALOVIRUS INFECTION AND DONOR/RECIPIENT HLA ANTIGENS: INTERDEPENDENT CO-FACTORS IN PATHOGENESIS OF VANISHING BILEDUCT SYNDROME AFTER LIVER TRANSPLANTATION , 1988, The Lancet.

[261]  U. Koszinowski,et al.  Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host , 1988, The Journal of experimental medicine.

[262]  A. Levey,et al.  Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. , 1987, The New England journal of medicine.

[263]  W. Britt,et al.  Primary Cytomegalovirus Infection in Pregnancy: Incidence, Transmission to Fetus, and Clinical Outcome , 1987 .

[264]  J. Nelson,et al.  Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. , 1985, Science.

[265]  S. Jonjić,et al.  Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs , 1985, Journal of virology.

[266]  R. Welsh,et al.  Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo , 1985, The Journal of experimental medicine.

[267]  B. Woda,et al.  Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. , 1983, Journal of immunology.

[268]  J. Manischewitz,et al.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. , 1982, The New England journal of medicine.

[269]  C. Alford,et al.  Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection. , 1982, The New England journal of medicine.

[270]  C. Prober,et al.  Prevention of Transfusion‐Acquired Cytomegalovirus Infections in Newborn Infants , 1981, The Journal of pediatrics.

[271]  F. Bia,et al.  Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus. , 1980, The Journal of infectious diseases.

[272]  M. Hilleman,et al.  Clinical and Laboratory Studies of Live Cytomegalovirus Vaccine Ad-169 , 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[273]  M. Stinski Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides , 1978, Journal of virology.

[274]  R. Hernández,et al.  Immunisation trials with live attenuated cytomegalovirus TOWNE 125 , 1975, Infection.

[275]  S. D. Elek,et al.  Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. , 1974, Lancet.

[276]  C. O. Kennedy A controlled trial , 1971, British Homeopathic Journal.

[277]  A. Limaye,et al.  Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. , 2008, The Journal of infectious diseases.

[278]  W. Chu,et al.  IFN-alphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. , 2007, Journal of immunology.

[279]  A. Akbar,et al.  Memory T cell homeostasis and senescence during aging. , 2005, Current opinion in immunology.

[280]  S. Boppana,et al.  Congenital cytomegalovirus infection: outcome and diagnosis. , 2005, Seminars in pediatric infectious diseases.

[281]  J. Bennink,et al.  A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways. , 2003, Viral immunology.

[282]  D. McGeoch,et al.  The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. , 2003, The Journal of general virology.

[283]  M. Messerle,et al.  Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. , 2002, Journal of virology.

[284]  G. Raghu,et al.  High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. , 2002, The Journal of infectious diseases.

[285]  J. Moreau,et al.  Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. , 2001, The Journal of infectious diseases.

[286]  D. Bernstein,et al.  Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection. , 2001, The Journal of infectious diseases.

[287]  I. Sia,et al.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. , 2000, Clinical microbiology reviews.

[288]  H. Ploegh,et al.  Viral subversion of the immune system. , 2000, Annual review of immunology.

[289]  H. Yoshida,et al.  Vgamma1+ gammadelta T cells play protective roles at an early phase of murine cytomegalovirus infection through production of interferon-gamma. , 2000, Immunology.

[290]  M. Bonneville,et al.  Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients. , 1999, The Journal of infectious diseases.

[291]  D. Sedmak,et al.  Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. , 1999, Journal of immunology.

[292]  M. Bonneville,et al.  Major Expansion of γδ T Lymphocytes following Cytomegalovirus Infection in Kidney Allograft Recipients , 1999 .

[293]  G. Hunninghake,et al.  Synergistic activation of the human cytomegalovirus major immediate early promoter by prostaglandin E2 and cytokines. , 1998, Experimental lung research.

[294]  K. Salmela,et al.  Persistent cytomegalovirus in liver allografts with chronic rejection. , 1997, Hepatology.

[295]  M. Roederer,et al.  Changes in antigen densities on leukocyte subsets correlate with progression of HIV disease. , 1996, International immunology.

[296]  E. Mocarski,et al.  Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. , 1995, Scandinavian journal of infectious diseases. Supplementum.

[297]  E. Paoletti,et al.  Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate. , 1995, Vaccine.

[298]  H. Volk,et al.  Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB. , 1995, Virology.

[299]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[300]  G. Alexander,et al.  Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. , 1988, Lancet.